Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID‐19 and similar lung diseases

At the end of 2019, respiratory coronavirus diseases 2019 (COVID‐19) appeared and spread rapidly in the world. Besides several mutations, the outcome of this pandemic was the death up to 15% of hospitalized patients. Mesenchymal stromal cell therapy as a therapeutic strategy seemed successful in tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Banimohamad‐Shotorbani, Behnaz, Farajpour, Hekmat, Sefat, Farshid, Khosroshahi, Shiva Ahdi, Shafaei, Hajar, Heidari keshel, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
REVIEWS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014656/
https://www.ncbi.nlm.nih.gov/pubmed/33629351
http://dx.doi.org/10.1002/bit.27729

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014656/
https://www.ncbi.nlm.nih.gov/pubmed/33629351
http://dx.doi.org/10.1002/bit.27729

Ejemplares similares